Capstan Medical
Capstan Medical is dedicated to transforming the treatment of structural heart disease by merging surgical robotics with catheter-based technology and next-generation implants. Their innovative platform offers a less invasive alternative to traditional open-heart surgery, aiming to improve patient outcomes, reduce recovery times, and minimize complications. Positioned in Santa Cruz, CA, they leverage local talent and a collaborative environment to develop groundbreaking solutions in cardiac healthcare.
Industries
Nr. of Employees
small (1-50)
Capstan Medical
2801 Mission St. Suite #239, Santa Cruz, CA
Patents
Products
Robotic-enabled transcatheter platform for mitral and tricuspid valve treatment
A system designed to enable robotic control of transcatheter delivery and deployment of valve implants in the mitral and tricuspid positions while the heart is beating; intended to provide a less invasive alternative to open-heart surgery.
Tissue-based mitral and tricuspid valve implants
Next-generation tissue valve implants intended for mitral and tricuspid replacement, with associated leaflet and subcomponent design and testing to support clinical use.
Catheter-based delivery systems and subassemblies
Delivery system hardware and subassemblies developed for precise deployment of structural heart implants, including steerable elements and electromechanical subcomponents for robotic integration.
Robotic-enabled transcatheter platform for mitral and tricuspid valve treatment
A system designed to enable robotic control of transcatheter delivery and deployment of valve implants in the mitral and tricuspid positions while the heart is beating; intended to provide a less invasive alternative to open-heart surgery.
Tissue-based mitral and tricuspid valve implants
Next-generation tissue valve implants intended for mitral and tricuspid replacement, with associated leaflet and subcomponent design and testing to support clinical use.
Catheter-based delivery systems and subassemblies
Delivery system hardware and subassemblies developed for precise deployment of structural heart implants, including steerable elements and electromechanical subcomponents for robotic integration.
Services
End-to-end clinical operations support for premarket device studies including protocol and ICF development, site activation and monitoring, CRO oversight, EDC management, and DSMB/CEC coordination.
Regulatory planning and preparation of submissions (PMA, IDE, 510(k), international registrations), regulatory liaison with authorities, and maintenance of device licensing and listing information.
Quality engineering support including process and packaging validation (IQ/OQ/PQ), sterilization and biocompatibility coordination, audit support, NCR/CAPA management, and finished‑goods release activities in a cleanroom environment.
End-to-end clinical operations support for premarket device studies including protocol and ICF development, site activation and monitoring, CRO oversight, EDC management, and DSMB/CEC coordination.
Regulatory planning and preparation of submissions (PMA, IDE, 510(k), international registrations), regulatory liaison with authorities, and maintenance of device licensing and listing information.
Quality engineering support including process and packaging validation (IQ/OQ/PQ), sterilization and biocompatibility coordination, audit support, NCR/CAPA management, and finished‑goods release activities in a cleanroom environment.
Expertise Areas
- Surgical robotics for cardiovascular procedures
- Catheter-based delivery systems
- Structural heart implant design and tissue processing
- Design verification and validation for implantable devices
Key Technologies
- Surgical robotics
- Catheter-based delivery systems
- Tissue-based heart valve implants
- Steerable catheters
News & Updates
Capstan Medical successfully completed the world's first robotic catheter mitral valve replacements, marking a significant milestone in minimally invasive heart valve treatment.
The company raised $110 million to advance its robotic heart valve treatment technology, aiming to improve outcomes for patients with structural heart disease.
With $31.4 million in new funding, Capstan Medical is leveraging robotics to revolutionize minimally invasive heart valve care.
An interview with Maggie Nixon, CEO of Capstan Medical, sharing her journey from athlete to medical device innovator.
Eclipse leads a $31.4M Series B funding round to support Capstan Medical's mission to bring robotic heart valve treatments to patients.
World’s First Robotic Catheter Mitral Valve Replacements Successfully Completed
Capstan Medical achieved a milestone by successfully completing the world's first robotic catheter mitral valve replacements.
Capstan Medical successfully completed the world's first robotic catheter mitral valve replacements, marking a significant milestone in minimally invasive heart valve treatment.
The company raised $110 million to advance its robotic heart valve treatment technology, aiming to improve outcomes for patients with structural heart disease.
With $31.4 million in new funding, Capstan Medical is leveraging robotics to revolutionize minimally invasive heart valve care.
An interview with Maggie Nixon, CEO of Capstan Medical, sharing her journey from athlete to medical device innovator.
Eclipse leads a $31.4M Series B funding round to support Capstan Medical's mission to bring robotic heart valve treatments to patients.
World’s First Robotic Catheter Mitral Valve Replacements Successfully Completed
Capstan Medical achieved a milestone by successfully completing the world's first robotic catheter mitral valve replacements.